0.85

0.01% -0.000050

Burning Rock Biotech Ltd ADR (BNR)

Overview News Price History Discussions Forecast

Burning Rock Biotech Ltd ADR stock is currently priced at $0.85, with a 24-hour trading volume of 30,333. It has seen a -0.01% decreased in the last 24 hours and a +21.43% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.8407 pivot point. If it approaches the $0.8894 resistance level, significant changes may occur.

Previous Close:

$0.8501

Open:

$0.8142

24h Volume:

30,333

Market Cap:

$87.27M

Revenue:

$79.32M

Net Income/Loss:

$-100.37M

P/E Ratio:

-0.795

EPS:

-1.0692

Net Cash Flow:

$-44.34M

1W Performance:

+18.06%

1M Performance:

+21.43%

6M Performance:

-20.56%

1Y Performance:

-71.09%

1D Range:

$0.7819

$0.88

52W Range:

$0.5722

$3.25

Burning Rock Biotech Ltd ADR Stock (BNR) Company Profile

Name

Burning Rock Biotech Ltd ADR

Sector

Healthcare (1191)

Industry

Diagnostics & Research (66)

Phone

86 20 3403 7871

Address

Building 3, Standard Industrial Unit 2, Room 601, 6th Floor No. 7, Luoxuan 4th Road International Bio Island, Guangzhou

Employee

753

Twitter

Next Earnings Date

2024-05-28

Latest SEC Filings

BNR's Discussions on Twitter

Burning Rock Biotech Ltd ADR Stock (BNR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-15-21	Resumed	Cowen	Outperform
Jul-07-20	Initiated	Cowen	Outperform

Burning Rock Biotech Ltd ADR Stock (BNR) Latest News

Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023

GlobeNewswire Inc.

Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023

GlobeNewswire Inc.

Burning Rock Biotech Ltd ADR Stock (BNR) Financials Data

Burning Rock Biotech Ltd ADR (BNR) Revenue 2024

BNR reported a revenue (TTM) of $79.32 million for the quarter ending September 30, 2023, a -8.53% decline year-over-year.

Burning Rock Biotech Ltd ADR (BNR) Net Income 2024

BNR net income (TTM) was -$100.37 million for the quarter ending September 30, 2023, a +34.75% increase year-over-year.

Burning Rock Biotech Ltd ADR (BNR) Cash Flow 2024

BNR recorded a free cash flow (TTM) of -$44.34 million for the quarter ending September 30, 2023, a +40.38% increase year-over-year.

Burning Rock Biotech Ltd ADR (BNR) Earnings per Share 2024

BNR earnings per share (TTM) was -$0.98 for the quarter ending September 30, 2023, a +33.43% growth year-over-year.

Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. It also offers liquid biopsy; OncoScreen Plus, a test for therapy and immunotherapy; LungPlasma, a test for non-small cell lung cancer, including various genes that have a targeted therapy; ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech was founded in 2014 and is headquartered in Guangzhou, China.